Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02561000 · ClinicalTrials.gov registry record · Phase 2

Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention

A Phase 2 study, sponsored by Tufts Medical Center.

Completed
Registry status
Phase 2
Development phase
100
Enrollment target

NCT02561000 is a Phase 2 study that has completed, run by Tufts Medical Center. The registered enrollment target is 100 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02561000, a Phase 2 study, has completed, sponsored by Tufts Medical Center.

COMPLETED
Registry status
Phase 2
Development phase
100 participants
Enrollment target

Study Summary

The object of the study is to determine whether different doses of PZ-128, when added to standard medical care in persons undergoing cardiac catheterization/percutaneous coronary intervention, will increase the risk of bleeding. A secondary objective is to determine whether patients treated with PZ-128 have fewer cardiac events such as heart attack, bypass surgery or stroke compared with those persons treated with the standard of care.

Interventions

  • DRUG Placebo
  • DRUG PZ-128

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2016-05-27
Est. Completion 2019-09-17
Phase Phase 2

Sponsor

Tufts Medical Center

169 total trials

What the Registry Record Tells You About NCT02561000

The ClinicalTrials.gov registry entry for NCT02561000 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02561000 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02561000 about?

NCT02561000 is a clinical study titled "Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention". The object of the study is to determine whether different doses of PZ-128, when added to standard medical care in persons undergoing cardiac catheterization/percutaneous coronary intervention, will increase the risk of bleeding. A secondary objective is to determine whether patients treated with PZ...

What is the current status of trial NCT02561000?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2016-05-27. Estimated completion is 2019-09-17.

What interventions are being tested in trial NCT02561000?

The interventions under investigation include: Placebo (DRUG), PZ-128 (DRUG).

Who is sponsoring clinical trial NCT02561000?

This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.